Replimune Announces Sander Slootweg will Depart from its Board of Directors

Replimune Announces Sander Slootweg will Depart

from its Board of Directors

WOBURN, Mass., July 20, 2023 - Replimune Group, Inc.

(NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies,

today announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director

at the end of his current term at the company's upcoming annual general meeting.

"It has been a pleasure working with Sander since the inception

of Replimune several years ago," said Philip Astley-Sparke, CEO of Replimune. "We are grateful for Sander's sage advice,

expertise and Forbion's support of Replimune, and the other directors and members of our executive team join me in wishing Sander

"I am incredibly proud of being part of the board, and especially

in what Replimune has accomplished since the company's founding," said Sander Slootweg, founder and managing partner at Forbion.

"It was our belief from the start that tumor-directed oncolytic immunotherapy had immense potential to benefit patients in a variety

of cancers, and I believe the company is well positioned to fulfill its promise."

Replimune Group, Inc., headquartered

in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed

oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize

immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic

mechanism of action consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens

and altering of the tumor microenvironment to ignite a strong and durable systemic response. This MOA is expected to be synergistic with

most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility

to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Forward Looking Statements

This press release contains forward looking statements within the meaning

of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,

including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes

to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient

enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as "could,"

"expects," "intends," "may," "plans," "potential," "should," "will,"

"would," or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees

of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could

cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related

to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing

of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which

we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including

the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time

in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange

Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking

statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking

Westwicke, an ICR Company